Astellas Gene Therapies, Inc. Overview
Pro stress-test →Astellas Gene Therapies is a developer of gene therapies for the treatment of rare diseases. The company aims to become a global leader in genetic medicines using adeno-associated viruses (AAVs) to introduce corrective genes into cells that have faulty or missing genes. The company has invested $100 million in a biomanufacturing facility in Sanford, North Carolina with the promise of creating more than 200 jobs through 2026.
Strategic Profile
Pro stress-test →Astellas Gene Therapies is exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown for targeted therapies. As of January 2026, instead of developing the AAV-based resamirigene bilparvovec (AT132) on its own, Astellas is partnering with Kate Therapeutics—acquired in 2024 by Novartis for up to $1.1 billion—to develop a MyoAAV capsid-based gene therapy for XLMTM.
Competitive Landscape
Pro stress-test →Top competitors include Alnylam, BridgeBio and Spark Therapeutics. The gene therapy landscape for rare diseases is increasingly competitive, with multiple AAV and non-AAV platforms advancing. Astellas' differentiation lies in its MyoAAV capsid partnership and manufacturing scale, though larger biotech and pharma players maintain broader resources and pipeline depth.
Industry Context
Astellas Gene Therapies, Inc. operates in Gene therapy for rare diseases.
Key facts
Founded: 2012 · Headquarters: San Francisco, US · Employees: 777 · Revenue: N/A · Market cap: N/A